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Abstract 
 
Introduction: Mesothelioma is a rare type of cancer that is strongly tied to asbestos exposure. 
Despite application of different modalities such as chemotherapy, radiotherapy and surgery, 
patient prognosis remains very poor and therapies are ineffective. Much research currently 
focuses on the application of novel approaches such as immunotherapy towards this disease. 
 
Areas Covered: The types, stages and aetiology of mesothelioma are detailed, followed by 
current treatment options such as radiotherapy, surgery and chemotherapy which are then 
discussed, followed by a description of innate and adaptive immunity and the principles and 
justification of immunotherapy. Clinical trials for different immunotherapeutic modalities are 
described, and lastly the article closes with an Expert Commentary and Five Year View, the 
former of which is summarised below. 
 
Expert Commentary: Current efforts for novel mesothelioma therapies have been limited by 
attempting to apply treatments from other cancers, an approach which is not based on a solid 
understanding of mesothelioma biology. In our view, the influence of the hostile, hypoxic 
microenvironment and the gene expression and metabolic changes that resultantly occur 
should be characterised to improve therapies. Lastly, clinical trials should focus on overall 
survival rather than surrogate endpoints to avoid bias and inaccurate reflections of treatment 
effects. 
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1. Introduction 
 
Mesothelioma is a general term referring to numerous different cancers that are typically 
related to asbestos exposure and develop from the normal mesothelial cells that line various 
organs. Mesothelioma is typically divided into four classifications: pleural mesothelioma 
(mesothelioma of the lungs); peritoneal mesothelioma (mesothelioma of the abdomen); 
pericardial mesothelioma (mesothelioma of the heart) and mesothelioma of the tunica 
vaginalis (testicular mesothelioma) [1,2]. Histologically, there are primarily three broad 
categories of mesothelioma: epithelioid (approximately 80%-90% of cases); biphasic 
(approximately 10-20% of cases) and sarcomatoid (also approximately 10-20% of cases) 
[1,3]. Epithelioid mesothelioma is characterised through rounded to cuboidal cells, whilst 
sarcomatoid mesothelioma is characterised by spindle-shaped cells and cause bulky and 
aggressive tumours [3]. Lastly, biphasic mesothelioma contains a mixture of sarcomatoid and 
epithelioid cells. The histological subtype of mesothelioma may be an important determinant 
of its treatability; although sarcomatoid mesothelioma is relatively rare, it is commonly 
known as an aggressive cancer and patients have a very poor prognosis [4]. 
 
Current treatments for mesothelioma remain ineffective, with no standard second-line therapy 
and no treatments that dramatically improve survival. This therefore represents a significant 
unmet need, as it is anticipated that the disease will peak between 2015-2030 due to the 
latency period of the disease [5]. Incidence rates for pleural mesothelioma vary among 
different countries, with approximately 2000-3000 cases per year in the USA, 1000-1500 
cases per year in the UK, and 1000 cases per year in Germany [4]. The latency period 
between asbestos exposure and disease onset leads to the delayed expected incidence peak, in 
addition to the fact that a quarter of a million deaths are expected from the disease in Europe 
within the next few years, due to occupational exposure [4]. 
 
This review will detail the pathogenesis of mesothelioma, in addition to its stages and the 
current approaches to treatment, both surgical (tumour resection and palliative care) and 
pharmacological (drugs such as gemcitabine, pemetrexed and cisplatin). After this, the basics 
of immunotherapy and its types and potential advantages will be discussed, followed by 
examples of application of immunotherapy to mesothelioma and current clinical trials. Lastly, 
the review closes with an Expert Commentary and Five Year View detailing our opinion on 
mesothelioma treatment and research directions in the present and coming years. 
 
2. Body 
 
2.1 Pathogenesis of Mesothelioma 
 
Development of mesothelioma is thought to be influenced by a variety of factors such as 
simian virus 40 (SV40), which has been shown to be present in some human mesothelial 
tumours. Further evidence for the role of SV40 in mesothelioma development can be seen 
through the fact that its intracardial injection into mice leads to the development of malignant 
mesothelioma in 60% of cases [6]. Other factors indicated as contributing to the development 
of mesothelioma include genetic susceptibility, in addition to ionising radiation; previous 
comprehensive reviews have indicated that although a definitive causal link could not be 
established, there was sufficient evidence for radiation exposure to at least be considered 
[7,8]. An additional risk factor is erionite, a naturally occurring mineral that has properties 
similar to asbestos [5]. 
 It is widely believed that asbestos exposure is perhaps the most common driver for 
mesothelioma development, as it has been estimated that approximately 70-80% of 
mesothelioma cases are related to occupational or environmental asbestos exposure [4]. It is 
significantly more probable that men develop the disease rather than women (at a ratio of 
approximately 4:1 – 8:1), again likely due to workplace exposure [9]. It is also recognised 
that there is a long latency period between asbestos exposure and mesothelioma development 
(consisting of multiple decades), which has led to the expectation that the disease will peak 
between 2015-2030 [5]. 
 
Asbestos is thought to contribute to mesothelioma development through the inhalation of 
asbestos fibres, which remain trapped in the lower third of the lung [2]. The unsuccessful 
clearance of these fibres leads to a chronic inflammatory state which may contribute to 
mesothelioma development [10]. It has been thought that the release of high-mobility group 
box 1 protein following induction of necrosis by asbestos exposure may cause a chronic 
inflammatory state, accumulation of macrophages and TNFα secretion. TNFα then promotes 
survival of mesothelial cells that have been genetically damaged through asbestos exposure 
via the activation of NF-κB [7,11,12]. In addition to asbestos alone, concomitant smoking 
may enhance the risk of developing a malignancy (non-small cell lung cancer) by up to sixty-
fold [2]. 
 
Despite the above, it is also recognised that not all individuals exposed to asbestos will 
develop mesothelioma, which implicates a role for the additional factors  such as genetic 
susceptibility. Further evidence for this is that mesothelioma clustering can be seen within 
some families [13]. In recent years BRCA1-associated protein 1 (BAP1) germline mutations 
have been identified as predisposing factors to mesothelioma pathogenesis, with some 
important differences in clinical outcomes observed between mesothelioma patients with 
germline BAP1 mutations, and those without [9,13]. In particular, it has been identified that 
mesothelioma patients with germline BAP1 mutations have a significantly higher survival 
(up to seven-fold, irrespective of gender and age) than patients with sporadic mesothelioma 
[9]. Thus, identification of genetic factors driving mesothelioma development and patient 
stratification based on these findings may improve patient prognosis and clinical outcomes. 
 
2.2 Symptoms and Diagnosis of Mesothelioma 
 
Diagnosis of mesothelioma is complicated by the fact that its symptoms are often 
nonspecific, as most patients present with a cough, shortness of breath, and difficult, laboured 
breathing [2,14]. Chest pain is also commonly presented, as are pleural effusions and 
dysphagia (difficulty in swallowing) may also occur, though typically later in the course of 
the disease. Peritoneal mesothelioma may present symptoms such as nausea, vomiting, loss 
of appetite and diarrhoea or constipation [14]. Thus, the lack of symptoms specific to the 
disease makes early diagnosis a difficult task. 
 
In order to effectively diagnose mesothelioma, a combination of pathology insight, 
examination, radiology and knowledge of the history of the patient’s asbestos exposure is 
required. For patients presenting with pleural effusion, cytological analysis of this may allow 
confirmation of diagnosis; in one-third of cases pleural fluid is positive for malignant cells 
[14]. However, the presence of malignant cells within pleural fluid alone is usually not 
enough to confirm diagnosis, and corroboration with clinical, radiological and cytological 
data is preferred [14]. A pleural biopsy may confirm diagnosis, and a computed tomography 
(CT) scan can identify the extent of the disease, whilst radiological approaches in general are 
essential for the diagnosis, staging and management of the disease [14]. Radiological 
approaches used for the diagnosis of mesothelioma include x-rays, CT scans, magnetic 
resonance imaging (MRI) scans and positron emission tomography (PET) imaging. The 
challenge with mesothelioma diagnosis, in addition to the lack of specific symptoms, is the 
fact that distinguishing malignant tumours from benign pleural diseases can be challenging. 
However PET imaging has been shown in one study to have 96.8% sensitivity and 88.5% 
specificity in distinguishing malignant from benign pleural disease [14,15]. 
 
2.3 Stages of Mesothelioma 
 
Various staging protocols have been established for mesothelioma development, usually for 
malignant pleural mesothelioma (MPM) as there is a lack of staging for other mesothelioma 
types [2]. Examples of staging protocols include the Butchart system (based on the spread of 
the disease irrespective of histology) and the Brigham system (based on surgical resectability 
and involvement of lymph nodes), however the most widespread staging system in terms of 
usage is that developed by the International Mesothelioma Interest Group (IMIG), which is 
more detailed and incorporates information on the tumour, node involvement, and metastasis 
(hence TNM system) [2,14,16]. 
 
Stage I MPM under the staging system developed by the IMIG includes lymph node-negative 
patients with minimal visceral pleural involvement and minimal tumour growth restricted to 
the parietal pleura, whilst stage II MPM is lymph node-negative and confluent superficial 
tumour growth on all pleural surfaces or involvement of the lung parenchyma or diaphragm 
[16]. Stage III, which represents the most common stage of disease presentation, consists of 
tumours which have metastasised to areas such as lymph nodes, or whose tumour has 
extended into the soft tissues of areas such as the chest well or pericardium. Lastly, stage IV 
MPM contains features such as locally advanced tumours invading the spine or ribs and 
patients may present with distant metastases [16]. A CT-PET staged series demonstrated that 
3% of patients presented with stage I, 9% stage II, 48% stage III and 40% at stage IV [17]. 
 
The staging system described above was based on analysis of a small retrospective surgical 
series and as such expansion of the patient cohort would be desirable [18]. To address this 
IMIG and the International Association for the Study of Lung Cancer Staging and Prognostic 
Factors Committee together initiated a multinational database based on twenty-nine centres 
on four continents and included 2,460 patients who passed the initial eligibility screen. This 
database indicated that current T descriptors should be maintained with the caveat that T1a 
and T1b be placed in a single T1 category. Similarly, pleural thickness had prognostic 
significance and was indicated to be further examined on future revisions of the staging 
system. It was proposed that N1 and N2 merge into N1, whilst N3 is relabelled to N2 [18]. 
 
Based on additional analyses the optimal stage groupings for the eighth edition of the staging 
system was: “stage IA (T1N0), stage IB (T2-3N0), stage II (T1-2N1), stage IIIA (T3N1), 
stage IIIB (T1-3N2 or any T4) and stage IV (any M1)” [18]. Developing a precise staging 
system is crucial, as the progress of mesothelioma and the stage at which it is diagnosed can 
have important implications for its treatability, as detailed in the next section. 
 
2.4 Current Treatments for Mesothelioma 
 
Mesothelioma may be treated through combination or individual application of radiotherapy, 
chemotherapy, and surgery. The stage of the disease is an important determinant of which 
approach to use, with earlier stages being generally more treatable and potentially resectable 
by surgery. 
 
2.4.1 Palliative and Curative Treatments for Mesothelioma 
 
Regrettably, current treatments for mesothelioma do not dramatically improve survival, and 
there is no standard second-line therapy. However, there are established treatments and 
therapeutic options which are broadly split into palliative care (to provide relief from 
symptoms and alleviate patient suffering) and curative treatments (to treat and eliminate the 
actual disease). Suggested criteria to stratify patients to curative treatments or palliative care 
have been described, such as the decision to employ palliative care if the patient has a poor 
nutritional state and general condition, stage III or IV mesothelioma, or biphasic or 
sarcomatoid mesothelioma regardless of its stage [19]. As previously described, sarcomatoid 
mesothelioma is especially difficult to treat and its patients have a very poor prognosis [4]. 
Converse to the justification for palliative therapy, treatment with a curative intent may be 
undertaken if the patient is less than seventy years old, has no significant cardiopulmonary 
compromise, has epithelioid mesothelioma and has no relevant accompanying disease [19]. 
 
2.4.2 Surgical Treatment of Mesothelioma 
 
Surgery may be employed as either palliative care or used with curative intent. Generally, 
curative surgery is attempted only for resectable tumours, which are generally stage I or stage 
II. Although the ideal result from surgery would be a complete removal of the tumour, this is 
applicable only for a minority of patients as over 80% of mesothelioma diagnoses occur in 
stage III or IV [16,20,21]. Thus, surgery is generally employed as palliative care, with the 
aim being reduction of the tumour mass to alleviate symptoms. Surgery may be employed 
individually for patients with resectable tumours, however it is generally combined with other 
therapeutic modalities such as chemotherapy or radiotherapy, as it has been shown that 
patients undergoing multimodality therapy had a median survival of twenty months against 
ten for surgery alone [22]. 
 
2.4.3 Radiotherapy for Mesothelioma 
 
Radiotherapy is a strategy which employs the use of high energy waves to damage cellular 
genetic material, thereby preventing tumour cell proliferation, and may be used with either a 
curative or palliative intent [23]. Although radiotherapy is employed to treat mesothelioma, 
for MPM it is difficult to achieve tumouricidal concentrations due to the growth pattern of the 
tumour around the lung [16] and thus for many years it was largely used as an adjuvant after 
surgery [24]. However, intensity-modulated radiotherapy (IMRT) which aims to deliver a 
homogenous dose to the entire tumour at a concentration low enough that underlying organs 
are not damaged [16], has also been employed. IMRT initially demonstrated troubling levels 
of toxicity, though later reports indicated that it can be delivered safely in the setting of 
surgery. However, questions regarding its use still remain [24].   
2.4.4 Chemotherapy for Mesothelioma 
 
Despite the relatively poor efficacy and clinical outcome, chemotherapy is employed for the 
treatment of mesothelioma, as some improvements in survival have been observed [4]. The 
cornerstone of chemotherapy for the treatment of mesothelioma is combination 
chemotherapy, due to the fact that combination chemotherapy generally leads to better 
therapeutic outcomes than single agent chemotherapy. Anti-folates (such as pemetrexed) are 
often used in conjunction with platinum-based therapy (such as cisplatin) as a first-line 
therapy for unresectable advanced-stage MPM, however there is no standard second-line 
therapy for patients who do not respond to this [25,26]. Other drugs, including gemcitabine, 
etoposide and doxorubicin have also been used for the treatment of mesothelioma, however 
outcomes remain poor as median survival for patients treated chemotherapy after diagnosis is 
only four to twelve months [3,27]. Thus, surgery, radiotherapy and chemotherapy, which are 
the cornerstones for treatment in other cancer types, are all of limited use in mesothelioma 
and therefore new approaches are urgently needed. 
 
2.5 Immunity and Immunotherapy 
 
2.5.1 Innate and Adaptive Immunity 
 
Protective mechanisms within the human body may generally be divided into innate or 
adaptive. Innate immunity is the first-line response to a pathogen but cannot provide long-
term protection, and may generally be through anatomic or chemical barriers, in addition to 
cellular responses [28]. Examples of anatomical barriers include the epithelial skin surfaces 
and glandular and mucosal surface, whilst examples of chemical barriers include 
antimicrobial substances such as lysozyme within acidic environments [28]. Cellular-based 
innate immunity requires either recognition of conserved molecular components on the 
surface of the pathogen, or recognition of intracellular receptors within the pathogen. These 
conserved molecular components are generally referred to as pathogen-associated molecular 
patterns (PAMPS) and cells such as dendritic cells (DCs), macrophages, neutrophils and 
monocytes recognise the PAMPS and through phagocytosis remove pathogens [28]. 
 
In addition to the cells listed previously, natural killer (NK) cells are also involved in innate 
immunity, providing protection through surveillance and detecting cells infected with viruses. 
Additionally, NK cells may target tumour cells or other normal cells through their lack of 
major histocompatibility complex (MHC) molecules, and can be activated through 
interleukin stimulation such as interleukin-2 (IL-2) treatment [28,29]. DCs also serve as a 
link between innate and adaptive immunity through two broad mechanisms. First, DCs are 
“sentinels” and capture, process and present antigens and migrate to lymphoid tissue to select 
T cells that react to the antigen. Secondly, DCs are “sensors” and thus respond to numerous 
environmental stimuli via differentiation or maturation [30]. NK cells have also been shown 
to serve as a bridge of sorts through the promotion of cross-presentation of tumour-derived 
antigens by DCs through the release of interferon-gamma (IFNγ) and tumour necrosis factor 
alpha (TNFα) which ultimately promotes antigen-specific CD8+ T cell (also known as 
cytotoxic T lymphocytes) activation [28,31]. 
 
Unlike innate immunity, adaptive immunity confers long-lasting protection against infectious 
agents through recognition and memory of specific antigens. Whilst innate immunity relies 
on the recognition of highly repetitive molecules, adaptive immunity instead requires 
recognition of specific antigens [28]. Adaptive immunity is dependent on receptors that are 
custom made based on recombination of gene segments and involves T lymphocytes, which 
mature in the thymus and are responsible for effecting cellular immune responses, and B 
lymphocytes, which are responsible for producing antibodies [32]. Mature T cells are 
activated following interaction between their T cell receptor (TCR) with antigenic peptides in 
complex with MHC molecules on antigen-presenting cells (APCs), with CD8+ T cells 
recognising MHC Class I molecules whilst CD4+ T cells (also called T helper cells) 
recognise MHC Class II molecules [32]. CD8+ T cells comprise the majority of circulating T 
cells and thus serve to remove cells harbouring pathogens such as viruses and transformed 
cells, whilst CD4+ cells produce cytokines that assist in the activity of other T cells [32]. 
Thus, innate and adaptive immunity together provide a robust defence for the body against 
pathogens and harmful cells. 
 
2.5.2 Immunotherapy 
 
Of all the new therapeutic modalities under investigation for cancer treatment, 
immunotherapy is one that has received significant attention [5,33]. Immunotherapy is an 
innovative approach that, rather than targeting cancer cells themselves via drug treatment, 
aims to stimulate the immune system to promote an anti-tumour immune effect [34]. Specific 
to MPM, the potential application of immunotherapy may be sound given that it has been 
shown that lymphocyte infiltration within the tumour mass correlated with improved patient 
prognosis [35,36]. 
 
Immunotherapy as a whole may be largely split into active immunotherapy and passive 
immunotherapy [37]. The difference lies in whether the immune system of the patient is 
stimulated in situ; passive immunotherapy generally isolates effectors in vitro before 
applying them to the patient, whilst active immunotherapy aims to stimulate the patient’s own 
immune system, primarily through vaccination [37]. It has been stated previously that a 
common shortcoming of passive immunotherapy is that it is likely to yield only a temporary 
benefit, whilst active immunotherapeutic strategies may offer long-term disease control 
through education of the host’s immune system [38]. Passive immunotherapy may typically 
be used when the patient’s immune system is weak or poorly responsive, whilst active 
immunotherapy requires that the patient’s immune system is responsive to challenge, will be 
competently stimulated and promote effector actions [39]. 
 
There are many types of immunotherapy (Figure 1) [39]. Examples of active 
immunotherapeutic approaches include vaccination (such as peptide-based and DC-based) 
and immune checkpoint inhibition whereas cytokine administration and adoptive cell transfer 
are examples of passive immunotherapy [39]. Numerous different immunotherapeutic 
approaches have been applied to mesothelioma, detailed below in the relevant subsections. 
 
2.6 Application of Immunotherapy to Mesothelioma 
 
2.6.1 Immunotherapeutic Vaccination 
 
Immunotherapeutic vaccination aims to induce tumour-specific immune responses in vivo 
and there are multiple types such as peptide vaccination (the most common) or DC-based 
vaccines [39]. Peptide vaccines contain immunogenic epitopes from tumour-specific or 
tumour-associated antigens (TSAs or TAAs respectively), which can arise from numerous 
sources including but not limited to mutated oncogenes or tumour suppressor genes, 
oncofoetal proteins, oncogenic viruses, cancer-testis antigens or overexpressed self-proteins 
[39]. It is thought that immunogenic recognition of these TSAs/TAAs can lead to specific 
immune responses against the tumour, hence why it is such an attractive prospect. This is 
particularly relevant for personal peptide-based vaccination (PPV) as it is based on the 
concept of strengthening the host’s existing immune response. 
 DCs represent an ideal “vehicle” for  cancer vaccines due to their ability to affect both the 
innate and adaptive immune responses, and DC-based vaccination primarily works through 
two approaches: in vivo direct targeting of antigens to DC receptors, and ex vivo generation of 
antigen-loaded DCs [39]. DC-based vaccination is an approach that remains under a 
significant degree of investigation, due to the long-held interest and potential of the approach. 
One method that has garnered particular interest is the use of autologous tumour cells as a 
source for TAAs, as theoretically they should provide the most comprehensive coverage of 
tumour-specific components available. Allogeneic tumour cells are also useful in providing 
TAAs through their continuing culture in vitro and thus may theoretically provide limitless 
TAAs and allow for large-scale production of vaccines that can be consistent between 
vaccine batches thus allowing for improved comparison of clinical outcomes [39]. 
Autologous tumour cell vaccination requires transfection of tumour cells to make them 
produce cytokines and co-stimulatory molecules followed by irradiation of the tumour cells. 
Irradiation of the tumour cells renders them inactive and thus their injection into patients is 
safe as the cells do not proliferate and present TAAs to T cells, thus promoting a tumour-
specific immune response [39]. 
 
Specific to mesothelioma, one frequently investigated protein is Wilms tumor 1 (WT1) due to 
the fact that it is overexpressed in MPM and immunohistochemical staining of WT1 is 
routinely used to aid in MPM diagnosis [40]. Numerous clinical trials of immunotherapeutic 
vaccination relating to mesothelioma have been performed, with examples listed in Table 1 
below: 
  
Table 1: Examples of clinical trials relating to vaccine immunotherapy in mesothelioma. An asterisk (*) indicates that the number of patients is 
the projected accrual, not the number actually enrolled. 
Clinical Trial 
Identifier 
Study Title Phase Number of Patients 
Status/Outcome of 
Study 
NCT01265433 
Randomized Study of 
Adjuvant WT-1 
Analogue Peptide 
Vaccine in Patients 
With Malignant Pleural 
Mesothelioma (MPM) 
After Completion of 
Combined Modality 
Therapy 
II 31 Ongoing 
NCT01890980 
Phase II Study of 
Adjuvant WT-1 
Analogue Peptide 
Vaccine in MPM 
II 60* Ongoing 
Patients After MSK10-
134 
NCT02649829 
Autologous Dendritic 
Cell Vaccination in 
Mesothelioma 
(MESODEC) 
I/II 20* Recruiting 
NCT02408016 
Genetically Modified T 
Cells in Treating 
Patients With Stage III-
IV Non-small Cell Lung 
Cancer or 
Mesothelioma 
I/II 20* Recruiting 
NCT01258868 
Tumor Cell Vaccines 
With ISCOMATRIX 
Adjuvant and Celecoxib 
in Patients Undergoing 
Resection of Lung and 
I 44 Terminated 
Esophageal Cancers and 
Malignant Pleural 
Mesotheliomas 
NCT00006216 
Vaccine Therapy and 
Ganciclovir in Treating 
Patients With 
Mesothelioma 
I 3-16* Unknown 
NCT00398138 
Vaccine Therapy and 
GM-CSF in Treating 
Patients With Acute 
Myeloid Leukemia, 
Myelodysplastic 
Syndromes, Non-Small 
Cell Lung Cancer, or 
Mesothelioma 
I 22 
Completed – results 
indicate T cell 
stimulation in 
leukaemia patients but 
median disease-free 
survival was not 
reached [41]. 
NCT00003974 
Vaccine Therapy in 
Treating Patients With 
I 20* 
Completed, but no 
results posted on 
Stage I, Stage II, or 
Stage IIIA Non-small 
Cell Lung Cancer or 
With Stage I or Stage II 
Mesothelioma 
ClinicalTrials.gov 
NCT00280982 
Dendritic Cell-based 
Immunotherapy in 
Mesothelioma 
I 10 
Completed – results 
indicate that the use of 
autologous tumour 
lysate-pulsed DCs was 
feasible, well tolerated 
and induced an immune 
response in patients. 
Though preliminary, 
results indicate that a 
subset of patients may 
benefit from this 
approach without 
significant side effects 
[42] 
NCT01569919 
A Phase II Trial to 
Assess TroVax® Plus 
Chemotherapy in 
Patients With Malignant 
Pleural Mesothelioma 
(SKOPOS) 
II 26* Unknown 
NCT02054104 
Adjuvant Tumor Lysate 
Vaccine and Iscomatrix 
With or Without 
Metronomic Oral 
Cyclophosphamide and 
Celecoxib in Patients 
With Malignancies 
Involving Lungs, 
Esophagus, Pleura, or 
I/II 21 
Participant recruitment 
suspended 
Mediastinum 
NCT01675765 
Safety and Efficacy of 
Listeria in Combination 
With Chemotherapy as 
Front-line Treatment for 
Malignant Pleural 
Mesothelioma 
I 60 Ongoing 
NCT01291420 
Dendritic Cell 
Vaccination for Patients 
With Solid Tumors 
I/II 10* 
Unknown – data 
presented at ASCO 
2014 suggest that the 
overall survival data is 
indicative that adjuvant 
DC-based therapy 
provides a clinical 
benefit for MPM 
patients [43]  
NCT02151448 αDC1 Vaccine + I/II 168* Recruiting 
Chemokine Modulatory 
Regimen (CKM) as 
Adjuvant Treatment of 
Peritoneal Surface 
Malignancies 
NCT00003263 
Cisplatin, Interferon 
Alfa, Surgery, and 
Radiation Therapy in 
Treating Patients With 
Malignant Pleural 
Mesothelioma 
I 6 
Completed, but no 
results posted on 
ClinicalTrials.gov 
NCT01503177 
Intrapleural Measles 
Virus Therapy in 
Patients With Malignant 
Pleural Mesothelioma 
I 36* Recruiting 
NCT02395679 
Dendritic Cells Loaded 
With Allogeneous Cell 
I 9* Unknown 
Lysate in Mesothelioma 
Patients 
(MesoCancerVa) 
NCT00002475 
Cyclophosphamide Plus 
Vaccine Therapy in 
Treating Patients With 
Advanced Cancer 
II 40* 
Completed, but no 
results posted on 
ClinicalTrials.gov 
NCT01241682 
Dendritic Cell-based 
Immunotherapy 
Combined With Low-
dose Cyclophosphamide 
in Patients With 
Malignant 
Mesothelioma (PMR-
MM-002) 
I 10 
Completed – results 
indicate that the 
treatment was safe, with 
the only side effect 
being moderate fever. 
Overall survival data 
was promising, with 
70% of patients 
surviving for at least 
two years and two 
patients alive after 50 
and 66 months [44] 
NCT02661100 
A Trial of CDX-1401 in 
Combination With 
Poly-ICLC and 
Pembrolizumab, in 
Previously Treated 
Advanced Solid Tumor 
Patients 
I/II N/A 
Withdrawn prior to 
enrolment 
NCT01997190 
Intrapleural AdV-tk 
Therapy in Patients 
With Malignant Pleural 
Effusion (MpeTK01) 
I 19* 
Ongoing – results 
presented at ASCO 
2016 indicate that Phase 
II studies may be 
warranted and that the 
intrapleural treatment 
can be safely 
administered, though 
side effects such as 
cytokine release 
syndrome, fever, nausea 
and chills were seen in 
some patients [45] 
NCT00423254 
Safety and Immune 
Response to a Multi-
component Immune 
Based Therapy 
(MKC1106-PP) for 
Patients With Advanced 
Cancer. 
I 24 
Completed – there was 
no partial or complete 
response according to 
RECIST criteria. 
Further investigation for 
specific clinical 
indications may be 
justified given that 15 of 
24 evaluable patients 
showed an immune 
response, whilst several 
patients  showed stable 
disease for six months 
or longer [46]  
NCT02714374 
Safety and Effect of 
GL-ONC1 
Administered IV With 
or Without Eculizumab 
Prior to Surgery to 
Patients With Solid 
Organ Cancers 
Undergoing Surgery 
I 36* Recruiting 
NCT02661659 
A Phase Ib Trial of a 
Maintenance 
Multipeptide Vaccine 
(S-588210) in Patients 
With Unresectable 
Malignant Pleural 
Mesothelioma Without 
I N/A 
Withdrawn prior to 
enrolment 
Progression After First-
Line Chemotherapy 
 
  
2.6.2 Immune Checkpoint Inhibition 
 
Within the healthy body, the immune system is tightly regulated both positively and 
negatively to ensure an appropriate immune response. Among these regulatory elements, 
immune checkpoints comprise a number of inhibitory pathways that serve as a way to 
maintain self-tolerance and minimise immune-mediated damage through modulating the 
length and strength of the response [47]. However, it is now apparent that this regulation is 
hijacked during the process of carcinogenesis and aberrantly regulated to allow cancer cells 
to evade immune detection. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and 
programmed cell death protein 1 (PD1) are two key negative regulators of the immune 
system and thus their blockage through antibodies or other treatments is currently under a 
significant degree of investigation as it is thought that if their expression is reduced, immune-
mediated tumour death could be enhanced (Figure 2) [47]. 
 
Immune checkpoint blockade has shown success in some other cancer types such as 
melanoma, where blockage of CTLA4 through ipilimumab (a mAb against CTLA4) has been 
approved for its treatment [21]. Similar to ipilimumab is tremelimumab, another mAb against 
CTLA4, which remains under investigation in many clinical trials though it is not yet 
approved for use in the clinic [5]. After the success of CTLA4 inhibition, the effects of PD1 
inhibition (through either targeting PD1 itself or its ligands) have also been assessed in 
clinical trials and currently pembrolizumab and nivolumab are approved for the treatment of 
metastatic melanoma [35,48]. 
 
Despite the application of immune checkpoint blockade in melanoma, these outcomes have 
not transferred to mesothelioma. One of the biggest trials for immune checkpoint blockade in 
mesothelioma was DETERMINE, which as of data presented at ASCO 2016 consisted of 571 
patients randomised to either placebo (n=189) or treated with tremelimumab (n=382) as a 
second- or third-line therapy [49]. The results for this trial presented at ASCO 2016 showed 
that 81% of patients died, whilst no statistically significant difference in overall survival 
between treated (median=7.7 months) and placebo (median 7.3 months) was observed [49]. 
The most frequent adverse events included diarrhoea, decreased appetite, dyspnoea, fatigue 
and nausea [49]. Results for PD1 inhibition initially appeared more promising; preliminary 
results for KEYNOTE-028, a trial assessing pembrolizumab in PD1-positive mesothelioma 
patients demonstrated a disease control rate of 76% and the drug was generally well tolerated 
[50]. Updated results (published May 2017) confirmed that the drug appeared to be well 
tolerated, indicated that pembrolizumab “might confer anti-tumour activity in patients with 
PD-L1-positive malignant pleural mesothelioma” and suggested that further investigations 
were warranted [51]. 
 
Although CTLA4 and PD1 are two of the most investigated markers, there are numerous 
other immune regulators which offer therapeutic potential. Among these are LAG3, TIM3, 
BTLA, 2B4, TIGIT and CD160 [52-54]. These are all involved in immune regulation in 
multiple ways; for instance LAG3 exerts a negative effect on T cell activation and effector 
functions via inhibition of CD4-dependent downstream signalling. Additionally, LAG3 
blockade has been demonstrated to lead to a reduction in the activity of immunosuppressive T 
regulatory cells [54], which distinguishes it from other targets such as CTLA4. Detailed 
coverage of the molecular signalling and potential therapeutic benefit of these and other 
markers have been comprehensively reviewed by Catakovic and colleagues [54]. To date, 
according to ClinicalTrials.gov, it appears that there are no trials for these targets in 
mesothelioma. However, at ASCO 2017 data on screening of PD-L1, PD-L2 and TIM3 from 
329 patients was presented which indicated that although co-expression can occur, these 
expressions were mutually exclusive in a large proportion of patients [52]. Therefore it has 
been argued that although CTLA4 and PD1 are among the most investigated targets, the role 
of these less well-understood markers and their clinical potential should be fully elucidated 
[52,53] 
 
Numerous  trials have been completed or are ongoing using different immune checkpoint 
inhibitors in mesothelioma, examples of which are shown in Table 2: 
  
Table 2: Examples of clinical trials relating to immune checkpoint blockade in mesothelioma. An asterisk (*) indicates that the number of 
patients is the projected accrual, not the number actually enrolled. 
Clinical Trial 
Identifier 
Study Title Phase Number of Patients 
Status/Outcome of 
Study 
NCT01843374 
Randomized, Double-
blind Study Comparing 
Tremelimumab to 
Placebo in Subjects 
With Unresectable 
Malignant 
Mesothelioma 
(Tremelimumab) 
II 658 
Ongoing – preliminary 
results presented at 
ASCO were detailed 
previously, but in brief 
81% of patients died 
and there was no 
statistically significant 
difference in overall 
survival between 
placebo and 
tremelimumab [49] 
NCT03075527 
A Phase 2 Study of 
Durvalumab in 
II 40* Recruiting 
Combination With 
Tremelimumab in 
Malignant Pleural 
Mesothelioma 
NCT02588131 
A Study of 
Tremelimumab 
Combined With the 
Anti-PD-L1 MEDI4736 
Antibody in Malignant 
Mesothelioma (NIBIT-
MESO-1) 
II 40* Recruiting 
NCT02592551 
MEDI4736 Or 
MEDI4736 + 
Tremelimumab In 
Surgically Resectable 
Malignant Pleural 
Mesothelioma 
II 20* Recruiting 
NCT02141347 
Ph1 to Assess Safety, 
Tolerability of 
Tremelimumab/ 
Tremelimumab+MEDI4
736 in Japanese Solid 
Malignancies/ 
Mesothelioma 
I 73 
Completed, but no 
results posted on 
ClinicalTrials.gov 
NCT01655888 
The Anti-CTLA-4 
Monoclonal Antibody 
Tremelimumab in 
Malignant 
Mesothelioma 
II 29 
Unknown – results 
published in 2015 
indicate that one patient 
(3%) achieved a partial 
response and 11 (38%) 
achieved disease control 
rate with a good safety 
profile. The most 
frequent treatment-
related adverse effects 
were gastrointestinal, 
fever and 
dermatological [55] 
NCT01649024 
A Clinical Study With 
Tremelimumab as 
Monotherapy in 
Malignant 
Mesothelioma 
II 29 
Unknown – results 
published in 2013 
indicate that no patients 
achieved a complete 
response, whilst only 
two (7%) had a durable 
partial response and the 
primary endpoint was 
not reached. Treatment-
emergent adverse 
effects were observed in 
93% of patients [56] 
NCT03126110 
Phase 1/2 Study 
Exploring the Safety, 
I/II 450* Recruiting 
Tolerability, and 
Efficacy of 
INCAGN01876 
Combined With 
Immune Therapies in 
Advanced or Metastatic 
Malignancies 
NCT02899299 
Study of Nivolumab 
Combined With 
Ipilimumab Versus 
Pemetrexed and 
Cisplatin or Carboplatin 
as First Line Therapy in 
Unresectable Pleural 
Mesothelioma Patients 
(CheckMate743) 
III 600* Recruiting 
NCT03048474 Ipilimumab and II 33* Recruiting 
Nivolumab in the 
Treatment of Malignant 
Pleural Mesothelioma 
(INITIATE) 
NCT02716272 
Nivolumab 
Monotherapy or 
Nivolumab Plus 
Ipilimumab, for 
Unresectable Malignant 
Pleural Mesothelioma 
(MPM) Patients 
(MAPS2) 
II 125 Ongoing 
NCT02054806 
Study of 
Pembrolizumab (MK-
3475) in Participants 
With Advanced Solid 
Tumors (MK-3475-
I 477 
Recruiting/Ongoing – 
results published in 
May 2017 indicate that 
the drug was well 
tolerated, might confer 
028/KEYNOTE-28) an anti-tumour effect 
and that further 
investigations were 
warranted [51] 
NCT02707666 
A Pilot Window-Of-
Opportunity Study of 
the Anti-PD-1 Antibody 
Pembrolizumab in 
Patients With 
Resectable Malignant 
Pleural Mesothelioma 
I 15* Recruiting 
NCT02991482 
PembROlizuMab 
Immunotherapy Versus 
Standard Chemotherapy 
for Advanced prE-
treated Malignant 
Pleural Mesothelioma 
III 142* Not yet recruiting 
(PROMISE-meso) 
NCT02784171 
Pembrolizumab in 
Patients With Advanced 
Malignant Pleural 
Mesothelioma 
II 126* Recruiting 
NCT02959463 
Adjuvant 
Pembrolizumab After 
Radiation Therapy for 
Lung-Intact Malignant 
Pleural Mesothelioma 
I 24* Recruiting 
NCT03126630 
Pembrolizumab With or 
Without Anetumab 
Ravtansine in Treating 
Patients With 
Mesothelin-Positive 
Pleural Mesothelioma 
I/II 134* Recruiting 
NCT02399371 Pembrolizumab in II 65* Recruiting 
Treating Patients With 
Malignant 
Mesothelioma 
NCT02758587 
Study of FAK 
(Defactinib) and PD-1 
(Pembrolizumab) 
Inhibition in Advanced 
Solid Malignancies 
(FAK-PD1) 
I/II 59* Recruiting 
NCT02661100 
A Trial of CDX-1401 in 
Combination With 
Poly-ICLC and 
Pembrolizumab, in 
Previously Treated 
Advanced Solid Tumor 
Patients 
I/II N/A 
Withdrawn prior to 
enrolment 
NCT02628067 Study of II 1350* Recruiting 
Pembrolizumab (MK-
3475) in Participants 
With Advanced Solid 
Tumors (MK-3475-
158/KEYNOTE-158) 
NCT02856425 
Trial Of Pembrolizumab 
And Nintedanib 
(PEMBIB) 
I 18* Recruiting 
NCT02419495 
Phase IB of Selinexor in 
Combination With 
Standard Chemotherapy 
in Patients With 
Advanced Malignancies 
I 588* Recruiting 
NCT03063450 
CheckpOiNt Blockade 
For Inhibition of 
Relapsed Mesothelioma 
(CONFIRM) 
III 336* Recruiting 
NCT02341625 
A Study of BMS-
986148 in Patients With 
Select Advanced Solid 
Tumors 
I/II 407* Recruiting 
NCT03071757 
A Study of the Safety, 
Tolerability and 
Pharmacokinetics of 
ABBV-368 as a Single 
Agent and Combination 
in Subjects With 
Locally Advanced or 
Metastatic Solid 
Tumors 
I 100* Recruiting 
NCT02497508 
Nivolumab in Patients 
With Recurrent 
Malignant 
Mesothelioma 
II 33 Ongoing 
(NivoMes) 
NCT02458638 
A Study of 
Atezolizumab in 
Advanced Solid Tumors 
II 725* Recruiting 
NCT03074513 
Atezolizumab and 
Bevacizumab in Rare 
Solid Tumors 
II 160* Recruiting 
NCT01772004 
Avelumab in Metastatic 
or Locally Advanced 
Solid Tumors 
(JAVELIN Solid 
Tumor) 
I 1706* 
Recruiting – 
preliminary safety data 
indicates an acceptable 
safety profile in pre-
treated populations [57] 
 
2.6.3 Oncolytic Virotherapy 
 
Oncolytic viruses are either genetically engineered or naturally occurring viruses that 
preferentially target tumour cells over healthy cells. In addition to this, they are capable of 
impairing abnormal vasculature and promote immune functions. Due to its potential, this 
approach has garnered increased interest in recent years, though questions over issues such as 
administration routes and the injection frequency required to achieve a therapeutic effect and 
theorising how the oncolytic viruses may evade immune detection remain [58]. Despite these 
issues, the challenging clinical management of diseases such as mesothelioma makes such 
diseases suitable candidates for innovative therapies. Particularly for MPM, treatment of 
pleural effusions requires access to the pleural cavity, and thus local injections of oncolytic 
viruses is a possibility [58]. 
 
The application of oncolytic virotherapy to the treatment of mesothelioma has been 
comprehensively reviewed by Boisgerault and colleagues in 2015  [58]. There are numerous 
types of oncolytic viruses such as herpesvirus, adenovirus and RNA viruses. An ongoing 
Phase I/II study sponsored by Virttu Biologics Limited (ClinicalTrials.gov identifier 
NCT01721018) is assessing the effect of intrapleural administration of HSV1716, a mutated 
herpes simplex virus. 12 MPM patients have been enrolled but the study’s results have not 
been posted yet (estimated completion is June 2017). Multiple trials have been initiated or are 
completed relating to virotherapy in mesothelioma (summarised in Table 1 in the manuscript 
by Boisgerault and colleagues [58]). A new Phase I/II trial (registered July 2016, 
ClinicalTrials.gov identifier NCT02879669) aims to assess the effects of ONCOS-12, an 
oncolytic adenovirus that primes the immune system in the treatment of unresectable MPM. 
The study aims to recruit 30 patients and its expected primary completion date is December 
2018. Another new Phase I study (registered March 2016, ClinicalTrials.gov identifier 
NCT02714374) aims to investigate GL-ONC1, a genetically modified vaccinia virus that may 
have an anti-tumour effect. The study aims to recruit 36 patients with solid tumours and has 
an estimated primary completion date of March 2018, with the overall study being completed 
in March 2020. Thus, in addition to the numerous trials described by Boisgerault and 
colleagues [58], trials remain ongoing and therefore oncolytic virotherapy is still under a 
degree of investigation. 
 
 
2.6.4 Cytokine Administration 
 
Cytokine administration was among the first therapeutic interventions in the treatment of 
cancer, though its use as a monotherapy is less common and it is now generally used in 
combination therapy [39]. Cytokine administration aims to provide a short-term “boost” to 
anti-tumour effects through temporary stimulation of the host’s immune system [35]. 
Numerous cytokines are utilised for this [39] but a common one is interleukin-2 (IL2). An 
early Phase II study with intrapleural IL2 administration with 22 mesothelioma patients 
indicated that there may be some beneficial effects of cytokine administration, with median 
survival of responders (28 months) being significantly longer than the median survival for 
non-responders (8 months) [53,59]. However, this initial positive result was hampered by 
further research and trials which demonstrated high treatment-related toxicity and side effects 
[53]. 
 
Despite the apparent failure of IL2 administration as a monotherapy, it is currently under 
investigation as part of multimodality therapy. A study sponsored by the University Health 
Network, Toronto is currently recruiting participants for a Phase I/II study that aims to 
examine the effect of tumour-infiltrating lymphocytes and low-dose IL2 therapy in pleural 
mesothelioma patients following treatment with cyclophosphamide and fludarabine. The 
study (ClinicalTrials.gov identifier NCT02414945) aims to recruit ten patients and has an 
estimated completion of November 2025. 
 
2.6.5 Monoclonal Antibody Therapy 
 
The overarching principle behind the use of mAbs in cancer therapy is to target cancer-
specific or cancer-associated antigens which the antibody binds to, ultimately resulting in an 
anti-tumour effect through a variety of mechanisms [39]. For mesothelioma, common 
antibody targets include mesothelin (highly expressed in mesothelioma) and TGF-β [35]. 
Monoclonal antibodies may be combined with other therapeutics to serve, for example, as 
vehicles for drugs. 
 
Mesothelin represents an interesting target as its high level of expression in mesothelioma 
results in it commonly being used as a serum biomarker for mesothelioma diagnosis [60] and 
thus there are several trials investigating its potential as a biomarker. Antibodies targeting 
mesothelin function through the antibody dependent cellular cytotoxicity (ADCC) 
mechanism, which confers specificity against mesothioloma tumors. In particular anti-
mesothelin antibodies recognize specifically the antigen (mesothelin) via their Fab domain 
whereas via their Fc domain they bind receptors on NK cells and recruit these cytotoxic cells 
in the neoplastic tissue thereby killing tumor cells overexpressing mesothelin. Comparatively, 
TGF- β is an interesting protein as in normal epithelial cells it is a potent growth inhibitor and 
promotes cellular differentiation. However, in the case of tumour progression, cancer cells 
lose their ability to respond to TGF-β and thus TGF-β becomes a key stimulator of 
angiogenesis, affects the microenvironment and causes immunosuppression [61]. Mesothelin 
and TGF-β are both thus interesting targets and there are numerous trials targeting them, with 
some examples of initiated, ongoing or completed trials listed in Table 3 below: 
  
Table 3: Examples of clinical trials relating to the use of monoclonal antibodies in mesothelioma. An asterisk (*) indicates that the number of 
patients is the projected accrual, not the number actually enrolled. 
Clinical Trial 
Identifier 
Study Title Phase Number of Patients 
Status/Outcome of 
Study 
NCT00325494 
A Study of MORAb-
009 in Subjects With 
Pancreatic Cancer, 
Mesothelioma, or 
Certain Types of 
Ovarian or Lung Cancer 
I 24 
Completed – results 
indicate that MORAb-
009 (also known as 
amatuximab) was well 
tolerated and that of the 
24 patients, 11 had 
stable disease [62] 
NCT00738582 
An Efficacy Study of 
MORAb-009 
(Amatuximab) in 
Subjects With Pleural 
Mesothelioma 
(Amatuximab) 
II 89 
Completed, but no 
results posted on 
ClinicalTrials.gov 
NCT01413451 
Amatuximab for High 
Mesothelin Cancers 
I 7 Terminated 
NCT01521325 
A Single-Dose Pilot 
Study of Radiolabeled 
Amatuximab (MORAb-
009) in Mesothelin 
Over Expressing 
Cancers 
I 6 
Completed, but no 
results posted on 
ClinicalTrials.gov 
NCT02357147 
Study of the Safety and 
Efficacy of 
Amatuximab in 
Combination With 
Pemetrexed and 
Cisplatin in Subjects 
With Unresectable 
Malignant Pleural 
Mesothelioma (MPM). 
II 108 Ongoing 
(ARTEMIS) 
NCT01112293 
Anti-TGF Monoclonal 
Antibody (GC1008) in 
Relapsed Malignant 
Pleural Mesothelioma 
II 13 
Completed – results 
indicate all patients 
tolerated the therapy, in 
addition to the fact that 
three patients showed 
stable disease at three 
months, although no 
partial or complete 
radiographic responses 
were observed [61] 
NCT01105390 
AMG 102, Pemetrexed 
Disodium, and Cisplatin 
in Treating Patients 
With Malignant Pleural 
Mesothelioma 
II N/A 
Withdrawn prior to 
enrolment 
NCT01160458 Phase II Study of IMC- II 20 Ongoing 
A12 in Patients With 
Mesothelioma Who 
Have Been Previously 
Treated With 
Chemotherapy 
NCT01445392 
SS1(dsFV)PE38 Plus 
Pemetrexed and 
Cisplatin to Treat 
Malignant Pleural 
Mesothelioma 
I 24 
Completed – results 
indicate that SS1P when 
given with pemetrexed 
and cisplatin was safe, 
well tolerated, and 
demonstrated an anti-
tumour effect in 
unresectable advanced 
MPM [63] 
NCT01898156 
Two-Part, Open-Label, 
Multi-Center, Phase 1/2 
Study of BIW-8962 as 
I/II 37 Terminated 
Monotherapy in 
Subjects With Lung 
Cancer 
NCT00996567 
A Study of Cetuximab 
Combined With 
Cisplatin or 
Carboplatin/Pemetrexed 
as First Line Treatment 
in Patients With 
Malignant Pleural 
Mesothelioma. 
(MesoMab) 
II 22 
Completed, but no 
results posted on 
ClinicalTrials.gov  
NCT03126630 
Pembrolizumab With or 
Without Anetumab 
Ravtansine in Treating 
Patients With 
Mesothelin-Positive 
I/II 134* Not yet recruiting 
Pleural Mesothelioma 
NCT01362790 
SS1P and Pentostatin 
Plus Cyclophosphamide 
for Mesothelioma 
I/II 55 Ongoing 
NCT01355965 
Autologous Redirected 
RNA Meso-CIR T Cells 
I 18 
Ongoing – initial results 
indicate that the 
treatment was safe, 
feasible, and without 
clear evidence of off-
target cytotoxicity, in 
addition to an anti-
tumour effect [64] 
NCT02341625 
A Study of BMS-
986148 in Patients With 
Select Advanced Solid 
Tumors 
I/II 407* Recruiting 
NCT02369198 MesomiR 1: A Phase I I 27 Completed 
Study of TargomiRs as 
2nd or 3rd Line 
Treatment for Patients 
With Recurrent MPM 
and NSCLC 
NCT01134250 
Combination Therapy 
of F16IL2 and 
Paclitaxel in Solid 
Tumour Patients 
I/II 96* Unknown 
NCT03007030 
Trial of Adcetris in 
CD30+ Malignant 
Mesothelioma 
II 50* Recruiting 
NCT01486368 
A Phase II Study of PF-
03446962 in Patients 
With Advanced 
Malignant Pleural 
Mesothelioma 
II 17 Completed 
NCT01439152 
Phase I Study to 
Determine the 
Maximum Tolerable 
Dose of BAY94-9343 
in Patients With 
Advanced Solid 
Tumors. 
I 147 
Ongoing – results 
presented at ASCO 
2016 indicated adverse 
events to include 
reversible keratopathy 
and gastrointestinal 
disorders though serious 
drug-related adverse 
events were low and 
there were no drug-
related deaths. 
Preliminary data 
showed durable partial 
responses in patients 
with advanced 
mesothelioma [65] 
NCT02610140 Phase II Anetumab II 248 Ongoing  
Ravtansine as 2nd Line 
Treatment for 
Malignant Pleural 
Mesothelioma (MPM) 
NCT02639091 
Phase Ib Study of 
Anetumab Ravtansine 
in Combination With 
Pemetrexed and 
Cisplatin in Mesothelin-
expressing Solid 
Tumors 
I 30* Recruiting 
NCT00024674 
Study of SS1(dsFv)-
PE38 (SS1P) Anti-
Mesothelin 
Immunotoxin in 
Advanced 
Malignancies: 
I N/A 
Withdrawn prior to 
enrolment 
Continuous Infusion for 
10 Days 
NCT00024687 
Study of SS1(dsFv)-
PE38 (SS1P) Anti-
Mesothelin 
Immunotoxin in 
Advanced 
Malignancies: IV 
Infusion QOD x Six 
Doses 
I N/A 
Withdrawn prior to 
enrolment 
NCT02661100 
A Trial of CDX-1401 in 
Combination With 
Poly-ICLC and 
Pembrolizumab, in 
Previously Treated 
Advanced Solid Tumor 
Patients 
I/II N/A 
Withdrawn prior to 
enrolment 
NCT03000257 
A Study of ABBV-181 
in Participants With 
Advanced Solid Tumors 
I 158* Recruiting 
NCT02714374 
Safety and Effect of 
GL-ONC1 
Administered IV With 
or Without Eculizumab 
Prior to Surgery to 
Patients With Solid 
Organ Cancers 
Undergoing Surgery 
I 36* Recruiting 
NCT02628535 
Safety Study of 
MGD009 in B7-H3-
expressing Tumors 
I 114* Recruiting 
NCT02485119 
Phase I Dose Escalation 
Study of BAY94-9343 
Given by Intravenous 
I 15* Ongoing 
Infusion Every 3 Weeks 
in Japanese Subjects 
With Advanced 
Malignancies 
NCT03126110 
Phase 1/2 Study 
Exploring the Safety, 
Tolerability, and 
Efficacy of 
INCAGN01876 
Combined With 
Immune Therapies in 
Advanced or Metastatic 
Malignancies 
I/II 450* Recruiting 
2.6.6 Adoptive Cell Transfer 
 
Adoptive cell transfer is a strategy that primarily relies on immune cells that have been 
“educated” ex vivo before the application of these autologous cells to the patient. The 
application of adoptive cell transfer through cells such as tumour-infiltrating lymphocytes 
represents a promising therapeutic strategy as it is backed by preclinical support and the 
autologous nature of the approach may improve its efficacy [66,67]. Education of these T 
cells may be via the transfection or transduction of chimeric antigen receptors (CARs) to the 
T cells, which allows the T cell to recognise tumour cells expressing TSAs or TAAs [53]. 
Frequent targets for adoptive cell transfer include fibroblast activation protein (FAP) and the 
aforementioned mesothelin [53]. Numerous trials relating to adoptive cell transfer in 
mesothelioma have been initiated, are ongoing or are completed, with examples listed below 
in Table 4: 
  
Table 4: Examples of clinical trials relating to the use of adoptive cell transfer in mesothelioma. An asterisk (*) indicates that the number of 
patients is the projected accrual, not the number actually enrolled. 
Clinical Trial 
Identifier 
Study Title Phase Number of Patients 
Status/Outcome of 
Study 
NCT01722149 
Re-directed T Cells for 
the Treatment (FAP)-
Positive Malignant 
Pleural Mesothelioma 
I 6* Recruiting 
NCT02408016 
Genetically Modified T 
Cells in Treating 
Patients With Stage III-
IV Non-small Cell Lung 
Cancer or 
Mesothelioma 
I/II 20* Recruiting 
NCT01355965 
Autologous Redirected 
RNA Meso-CIR T Cells 
I 18 
Ongoing – initial results 
indicate that the 
treatment was safe, 
feasible, and without 
clear evidence of off-
target cytotoxicity, in 
addition to an anti-
tumour effect [64] 
NCT02159716 
CART-meso in 
Mesothelin Expressing 
Cancers 
I 19 Ongoing 
NCT02414269 
Malignant Pleural 
Disease Treated With 
Autologous T Cells 
Genetically Engineered 
to Target the Cancer-
Cell Surface Antigen 
Mesothelin 
I 24* Recruiting 
NCT03054298 
CAR T Cells in 
Mesothelin Expressing 
I 30* Recruiting 
Cancers 
NCT02580747 
Treatment of Relapsed 
and/or Chemotherapy 
Refractory Advanced 
Malignancies by 
CART-meso 
I 20* Recruiting 
NCT01583686 
CAR T Cell Receptor 
Immunotherapy 
Targeting Mesothelin 
for Patients With 
Metastatic Cancer 
I/II 136* Recruiting 
3. Conclusions 
 
The “orphan” status of mesothelioma in terms of the lack of beneficial treatments creates a 
pressing need to uncover novel therapeutics to improve the outcomes for this disease whose 
incidence peak is anticipated to occur in the coming years. The fact that therapies proven 
effective for multiple other cancer types such as tyrosine kinase inhibition have demonstrated 
little therapeutic benefit other than bevacizumab for newly-diagnosed mesothelioma is 
surprising and indicates mesothelioma as a particularly aggressive or unique tumour. 
 
Innovative approaches such as immunotherapy have been successfully applied and approved 
in other cancer types, leading to the investigation of such approaches in mesothelioma, as is 
apparent from the large number of clinical trials that have been initiated, are ongoing, or are 
completed. Although there has been a significant degree of hope for the role of 
immunotherapy as a treatment for mesothelioma, clinical trial results remain largely 
disappointing. Immunotherapy for mesothelioma is likely complicated by the chronic 
inflammatory state that drives mesothelioma development. Different approaches to 
immunotherapy,  includingcytokine administration or immune checkpoint blockade, have 
demonstrated relatively high levels of treatment-related adverse events and the therapeutic 
benefit remains unclear. 
 
Despite the negative outcomes of numerous trials, it is clear that there are many approaches 
under investigation at different clinical trial phases. It is hoped that these investigations could 
yield a therapeutic benefit to alleviate the suffering of mesothelioma patients, though in 
addition to monitoring effects on survival (particularly overall instead of progression-free) 
the degree and frequency of treatment-related adverse events should be carefully monitored.  
4. Expert Commentary 
 
In recent years there has been an increased interest in developing improved therapeutics for 
the treatment of mesothelioma. Although undoubtedly welcome, efforts have been focussed 
largely on applying existing therapies from other cancers such as immune checkpoint 
blockade or tyrosine kinase inhibition to mesothelioma. Though such approaches have 
promoted improved clinical outcomes in numerous cancer types, such success has generally 
not been seen in mesothelioma, with most clinical trials reporting negative results. 
 
It is therefore our opinion that the development of novel therapeutics should focus not on 
applying therapies from other cancers, but should instead be based on a detailed 
understanding of the specific factors driving the carcinogenesis and resistance of 
mesothelioma. In particular, it is widely established that the hypoxic microenvironment of 
mesothelioma can have significant influence on the gene expression profile of mesothelioma 
cells, with microenvironment constituents such as stromal cells playing key roles in this. 
 
The chronic inflammation that drives mesothelioma leads to an altered immune response, 
which may partially explain the general lack of efficacy of immunotherapy. Similarly, the 
low mutational load of mesothelioma relative to other cancer types presents an additional 
explanation for potential reasons for therapy failure. If one also considers the difficulty to 
apply the immune-related response criteria to MPM and the rate and degree of side effects it 
is obvious that particular caution is needed before drawing conclusions. Although many trials 
for immunotherapeutic modalities have shown failure or limited benefit, some results from 
pembrolizumab still need to be validated in randomized clinical trials aiming to assess its real 
impact on the overall survival of patients. 
Examination of the mechanisms that mesothelioma cells use to survive within their hostile 
microenvironment and tolerate the gene and metabolic changes that occur should be 
examined in detail, as elucidation of these mechanisms may provide “druggable” targets in 
addition to insight into altered pathways driving mesothelioma development. In our view, 3D 
tissue culture models such as organoids, accurate in vitro simulation of the microenvironment 
and immune system, and lastly the use of primary cells wherever possible will all facilitate 
our improved understanding of factors contributing towards the carcinogenesis of 
mesothelioma. 
 
It has recently been demonstrated that surrogate end points for clinical trials such as 
progression-free survival do not fully reflect overall survival for immunotherapy trials and 
may often be significantly different [68]. Caution has therefore been advised when analysing 
results containing only progression-free survival and not overall survival data. Future trials 
should aim to include information on overall survival wherever possible so as to provide the 
most comprehensive information available. 
 
Ultimately, despite the fact that mesothelioma is still very much an orphan disease, there has 
been an increased interest in recent years and we hope that this increased interest will 
eventually lead to improved therapies and clinical outcomes for patients. By achieving a 
precise understanding of mesothelioma carcinogenesis we may be able to isolate essential 
factors and thus identify potential routes for the development of novel therapeutics. 
 
 
  
5. Five-Year View 
 
Immunotherapy remains highly investigated across numerous different diseases, including 
mesothelioma, likely due to the success of the approach in diseases such as melanoma. 
Although approaches such as interleukin-2 administration have demonstrated a therapeutic 
effect, these benefits are limited through treatment-related toxicity and side effects. Similarly, 
although immune checkpoint blockade remains highly investigated, results for mesothelioma 
have been disappointing. 
 
We anticipate that in the coming years immunotherapy will continue to be investigated due 
the high number of clinical trials (detailed in the tables of this article) that are in the 
recruitment or pre-recruitment stages. As suggested by Thapa and colleagues, it may be 
worth uncovering the biology behind immune checkpoints other than PD1 and CTLA4 and 
developing clinical trials for inhibitors against them as these under-investigated targets may 
represent novel therapeutic avenues [53]. 
 
Researching immunotherapy should take into consideration the role of the microenvironment 
as it is readily apparent that hypoxia and the chronic inflammation that defines mesothelioma 
leads to an altered immune response. Both of these factors are under increased investigation 
and we anticipate that elucidation of these factors may alter and improve research focus. 
 
Lastly, the recent argument that surrogate endpoints (such as progression-free survival) do 
not fully reflect the endpoint of overall survival in terms of treatment effect size [68] may 
promote an altered approach to trials, by aiming to report overall survival and base 
conclusions on this rather than potentially misleading surrogate endpoints.  
Key Issues 
 
 Mesothelioma is a rare, aggressive cancer whose incidence is expected to peak in the 
coming years 
 Current treatments do not significantly prolong survival, and clinical outcomes remain 
poor 
 Immunotherapy is a widely-investigated approach that aims to utilise the patient’s 
own immune system against tumours 
 Numerous immunotherapeutic approaches such as peptide, DC-based and autologous 
or allogeneic vaccination, immune checkpoint blockade and cytokine administration 
exist 
 Although immune checkpoint blockade has shown effect in melanoma, this approach 
has demonstrated a very limited benefit in mesothelioma 
 In addition to monitoring of overall survival instead of progression-free survival or 
other surrogate endpoints, side effects of immunotherapeutic approaches should also 
be considered 
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 Figure 1: Overview of different immunotherapeutic strategies. 
  
 Figure 2: A) The activation of naïve T cell requires signalling from TCR (signal 1) and CD28 (signal 2) 
which are expressed on their surface while CTLA4 is expressed intracellularly until TCR interacts with 
antigen from APC cells which promotes the migration of CTLA4 on the surface to attenuate the T cell 
response from TCR and CD28. Anti-CTLA4 antibodies block the interaction of CTLA4 with the ligand 
(CD80), allowing for enhanced anti-tumour response. B) PD1 is upregulated on T cell following the 
activation of T cell by TCR signalling and positive signals. PD1 receptor interaction with the ligand PDL1 
leads to attenuation of immune response. Anti-PD1/PDL1 antibodies block this signalling to enhance a 
antitumor immune response. 
Abbreviations : CTLA4, cytotoxic T-lymphocyte antigen 4; PD1, programmed death 1; PDL1, 
programmed death ligand 1; APC, antigen presenting cell; MHC, major histocompatibility complex; TCR, 
T cell receptor. 
 
 
